+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Gastrointestinal stromal tumors (GIST): at the forefront of targeted therapies



Gastrointestinal stromal tumors (GIST): at the forefront of targeted therapies



Medecine Sciences 29(6-7): 630-636



Although gastrointestinal stromal tumors (GIST) are the most frequent sarcomas, they were usually not diagnosed before 1998. GIST derive from interstitial cells of Cajal, and may develop along the digestive tract, mainly from stomach and small intestine. GIST are characterized by the expression of KIT (CD117), and mutations KIT or PDGFRA are present in 85 % of cases. More than 150 different types of mutations have been reported. They are responsible for a constitutive activation of these tyrosine kinase receptors, in absence of their specific ligand. Detection of these mutations may help to confirm the diagnosis or to evaluate the prognosis. The mutations also have a predictive value. Indeed patients with metastatic GIST and duplication within exon 9 of KIT deserve to receive twice the dose of imatinib, while GIST with PDGFRA p.D842 V mutation are resistant to this drug. This review presents the main characteristics of GIST, and focus on the important insights of studies on GIST and their cell models in the field of oncology.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053355287

Download citation: RISBibTeXText

PMID: 23859518

DOI: 10.1051/medsci/2013296016


Related references

Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers. Biochemical Pharmacology 80(5): 575-583, 2010

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). Oncotarget 6(4): 1954-1966, 2015

Gastrointestinal stromal tumors (GIST)--a paradigm of successful targeted therapy of solid tumors. Acta Medica Croatica 60(5): 471-475, 2007

The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations. Polski Przeglad Chirurgiczny 86(7): 325-332, 2016

Gastrointestinal stromal tumors (GIST): factors predictive of survival after R0-cytoreduction FT Tumores del estroma gastrointestinal (GIST): factores pronosticos de supervivencia tras citorreduccion R0. 2007

Targeted therapies in gastrointestinal stromal tumors. Seminars in Diagnostic Pathology 25(4): 295-303, 2008

Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathology and Oncology Research 9(1): 13-19, 2003

Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies. Pathology Research International 2011: 708596-708596, 2011

Predictors of response to targeted therapies for gastrointestinal stromal tumors. Archives of Pathology & Laboratory Medicine 136(5): 483-489, 2012

A role for adjuvant RFA in managing hepatic metastases from gastrointestinal stromal tumors (GIST) after treatment with targeted systemic therapy using kinase inhibitors. Cardiovascular and Interventional Radiology 37(1): 132-139, 2015

Pathology of gastrointestinal stromal tumors (GIST) FT Pathologie gastrointestinaler Stromatumoren (GIST). 2007

The criteria of aggressiveness and other prognostic factors for predicting relapses of primary tumors and imatinib (IM) treatment outcomes in advanced KIT immunopositive gastrointestinal stromal tumors (GIST): A report of the Polish Clinical GIST Registry (PCGR). Journal of Clinical Oncology 24(18_suppl): 9544-9544, 2016

Epidemiology, clinical picture, and diagnosis of gastrointestinal stromal tumors (GIST) FT Epidemiologie, Klink und Diagnostik von gastrointestinalen Stromatumoren (GIST). 2007

Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. International Journal of Clinical and Experimental Pathology 3(5): 461-471, 2010